PT  - JOURNAL ARTICLE
AU  - Albright, Catherine
AU  - Van Egeren, Debra
AU  - Thakur, Aditya
AU  - Chakravarty, Arijit
AU  - White, Laura F.
AU  - Stoddard, Madison
TI  - Antibody escape, the risk of serotype formation, and rapid immune waning: modeling the implications of SARS-CoV-2 immune evasion
AID  - 10.1101/2023.01.25.23285031
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.25.23285031
4099  - http://medrxiv.org/content/early/2023/05/04/2023.01.25.23285031.short
4100  - http://medrxiv.org/content/early/2023/05/04/2023.01.25.23285031.full
AB  - As the COVID-19 pandemic progresses, widespread community transmission of SARS-CoV-2 has ushered in a volatile era of viral immune evasion rather than the much-heralded stability of “endemicity” or “herd immunity.” At this point, an array of viral variants has rendered essentially all monoclonal antibody therapeutics obsolete and strongly undermined the impact of vaccinal immunity on SARS-CoV-2 transmission. In this work, we demonstrate that antigenic drift resulting in evasion of pre-existing immunity is highly evolutionarily favored and likely to cause waves of short-term transmission. In the long-term, invading variants that induce weak cross-immunity against pre-existing strains may co-circulate with those pre-existing strains. This would result in the formation of serotypes that increase disease burden, complicate SARS-CoV-2 control and raise the potential for increases in viral virulence. Less durable immunity does not drive positive selection as a trait, but such strains may transmit at high levels if they establish. Overall, our results draw attention to the importance of inter-strain cross-immunity as a driver of transmission trends and the importance of early immune evasion data to predict the trajectory of the pandemic.Competing Interest StatementMS and AC are employees of, and shareholders of, Fractal Therapeutics. Fractal Therapeutics has no commercial interest in the subject of this paper.Funding StatementL.F.W. received funding through National Institutes of Health, award number R35GM141821.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are contained in the manuscript. Code used to produce the results is available on Github. https://github.com/madistod/two-strain-SEIR